肝癌围手术期的免疫治疗

徐彬; 李美龄; 孙惠川

doi:10.3969/j.issn.1001-5256.2022.05.002

肝癌围手术期的免疫治疗

DOI: 10.3969/j.issn.1001-5256.2022.05.002

复旦大学附属中山医院肝肿瘤外科，上海 200032

基金项目:

国家重点基础研究发展规划(973计划)项目 (2015CB554005);

国家自然科学基金 (81372655);

国家自然科学基金 (81472224);

国家自然科学基金 (81672326);

上海市优秀学术/技术带头人计划 (17XD1401100)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：徐彬、李美龄负责文献查阅，论文撰写；孙惠川拟定写作思路，指导文章撰写及修改文章并最终定稿。

详细信息

通信作者:
孙惠川，sun.huichuan@zs-hospital.sh.cn

计量
- 文章访问数: 972
- HTML全文浏览量: 439
- PDF下载量: 189
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-14
- 录用日期: 2022-02-15
- 出版日期: 2022-05-20

Perioperative immunotherapy for hepatocellular carcinoma

Department of Liver Tumor Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Research funding:

National Key Basic Research Program (973 Program) (2015CB554005);

National Natural Science Foundation of China (81372655);

National Natural Science Foundation of China (81472224);

National Natural Science Foundation of China (81672326);

Leading Investigator Program of Shanghai Municipal Government (17XD1401100)

More Information

Corresponding author: SUN Huichuan, sun.huichuan@zs-hospital.sh.cn(ORCID: 0000-0003-3761-7058)

摘要

摘要: 肝细胞癌(以下简称肝癌)严重威胁我国人民的生命和健康。大多数肝癌患者在就诊时已处于中晚期，不适合接受根治性治疗；适合接受根治性治疗的早期肝癌患者仍然面临着术后较高的复发风险。鉴于以免疫检查点抑制剂为核心的免疫治疗方案在中晚期肝癌领域取得了重要进展，肝癌患者的围手术期免疫治疗也逐渐受到重视。在围手术期应用免疫治疗可以提高手术切除的可行性、降低手术切除后的复发率和延长患者生存。本文对以免疫检查点抑制剂为主的免疫治疗在肝癌围手术期中的应用和需要关注的问题进行探讨，希望能够为肝癌围手术期的免疫治疗提供新的思路。
- 癌，肝细胞 /
- 免疫治疗 /
- 新辅助治疗 /
- 转化治疗 /
- 辅助治疗
Abstract: Hepatocellular carcinoma (HCC) greatly threatens the life and health of Chinese people. Most patients with HCC are already in the advanced stage when attending the hospital and are not eligible for radical treatment, and patients in the early stage of HCC who are eligible for radical treatment still face a high risk of recurrence after surgery. In recent years, immunotherapy based on immune checkpoint inhibitors (ICIs) has made great progress in the treatment of advanced HCC, and perioperative immunotherapy for HCC is attracting more and more attention. Immunotherapy in the perioperative period of HCC can improve the feasibility of hepatectomy, reduce the recurrence rate after hepatectomy, and prolong the survival of patients. This article discusses the application of ICIs-based immunotherapy in the perioperative period of HCC and the issues that need to be considered, so as to provide new ideas for perioperative immunotherapy for HCC.
- Carcinoma, hepatocellular /
- Immunotherapy /
- Neoadjuvant therapy /
- Conversion therapy /
- Adjuvant therapy

HTML全文

参考文献(32)

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[3]	ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
[4]	LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
[5]	CHEN L, FLIES DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013, 13(4): 227-242. DOI: 10.1038/nri3405.
[6]	HE X, XU C. Immune checkpoint signaling and cancer immunotherapy[J]. Cell Res, 2020, 30(8): 660-669. DOI: 10.1038/s41422-020-0343-4.
[7]	YAU T, PARK J W, FINN R S, et al. CheckMate 459: A randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) [J]. Ann Oncol, 2019, 30: v874-v875. DOI: 10.1093/annonc/mdz394.029
[8]	FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307.
[9]	ZHU XD, LI KS, SUN HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects[J]. Genes Dis, 2020, 7(3): 359-369. DOI: 10.1016/j.gendis.2020.02.002.
[10]	SUN HC. Conversion surgery for unresectable or advanced hepatocellular carcinoma[J]. J Abdominal Surg, 2021, 34(2): 85-87. DOI: 10.3969/j.issn.1003-5591.2021.02.001. 孙惠川. 不可切除和中晚期肝癌的转化切除[J]. 腹部外科, 2021, 34(2): 85-87. DOI: 10.3969/j.issn.1003-5591.2021.02.001.
[11]	PINATO DJ, FESSAS P, SAPISOCHIN G, et al. Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma[J]. Hepatology, 2021, 74(1): 483-490. DOI: 10.1002/hep.31697.
[12]	MILLER BC, SEN DR, AL ABOSY R, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade[J]. Nat Immunol, 2019, 20(3): 326-336. DOI: 10.1038/s41590-019-0312-6.
[13]	LIU J, O'DONNELL JS, YAN J, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome[J]. Oncoimmunology, 2019, 8(5): e1581530. DOI: 10.1080/2162402X.2019.1581530.
[14]	YARCHOAN M, ZHU Q, DURHAM J N, et al. Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC) [J]. J Clin Oncol, 2021, 39(3_suppl): 335. DOI: 10.1200/JCO.2021.39.3_suppl.335
[15]	XIA Y, WANG P, PU L, et al. Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase Ⅱ study [J]. J Clin Oncol, 2021, 39(15_suppl): 4082. DOI: 10.1200/JCO.2021.39.15_suppl.4082
[16]	KASEB AO, HASANOV E, CAO H, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218. DOI: 10.1016/S2468-1253(21)00427-1.
[17]	YU YQ, TANG ZY, ZHOU XD, et al. Staged treatment of large hepatocellular carcinoma [J]. Chin J Surg, 1983, 21(2): 92-93. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906049.htm 余业勤, 汤钊猷, 周信达, 等. 大肝癌的分阶段治疗[J]. 中华外科杂志, 1983, 21(2): 92-93. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906049.htm
[18]	ZHU XD, HUANG C, SHEN YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4): 320-329. DOI: 10.1159/000514313.
[19]	ZHANG W, HU B, HAN J, et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: A pilot study of ten patients[J]. Front Oncol, 2021, 11: 747950. DOI: 10.3389/fonc.2021.747950.
[20]	YANG X, XU H, ZUO B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy[J]. Hepatobiliary Surg Nutr, 2021, 10(4): 434-442. DOI: 10.21037/hbsn-21-188.
[21]	ZHANG J, ZHANG X, MU H, et al. Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: A retrospective study[J]. Front Oncol, 2021, 11: 729764. DOI: 10.3389/fonc.2021.729764.
[22]	KRALL JA, REINHARDT F, MERCURY OA, et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy[J]. Sci Transl Med, 2018, 10(436): eaan3464. DOI: 10.1126/scitranslmed.aan3464.
[23]	ISHIKAWA M, NISHIOKA M, HANAKI N, et al. Perioperative immune responses in cancer patients undergoing digestive surgeries[J]. World J Surg Oncol, 2009, 7: 7. DOI: 10.1186/1477-7819-7-7.
[24]	DBROWSKA AM, SŁOTWIŃSKI R. The immune response to surgery and infection[J]. Cent Eur J Immunol, 2014, 39(4): 532-537. DOI: 10.5114/ceji.2014.47741.
[25]	KUDO M. Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis, ASCO Annual Meeting, F, 2021[C]. American Society of Clinical Oncology.
[26]	YANG X, SUN H, HU B, et al. 944P Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC Ⅱ and Ⅲ stage: A single-center prospective phase Ⅱ trial [J]. Annals Oncol, 2021, 32: S824.
[27]	DUAN J, CUI L, ZHAO X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: A systematic review and meta-analysis[J]. JAMA Oncol, 2020, 6(3): 375-384. DOI: 10.1001/jamaoncol.2019.5367.
[28]	BERTRAND A, KOSTINE M, BARNETCHE T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis[J]. BMC Med, 2015, 13: 211. DOI: 10.1186/s12916-015-0455-8.
[29]	ZHU A X, FINN R S, IKEDA M, et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2020, 38(15_suppl): 4519. DOI: 10.1200/JCO.2020.38.15_suppl.4519
[30]	XU B, SUN HC. Camrelizumab: An investigational agent for hepatocellular carcinoma[J]. Expert Opin Investig Drugs, 2021: 1-10. DOI: 10.1080/13543784.2022.2022121.
[31]	SANGRO B, CHAN SL, MEYER T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 320-341. DOI: 10.1016/j.jhep.2019.10.021.
[32]	SHI GM, HUANG XY, REN ZG, et al. Chinese expert consensus on the management of immune-related adverse events of hepato-cellular carcinoma treated with immune checkpoint inhibitors (2021 edition)[J]. Chin J Dig Surg, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594. 施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.